Immunorex TM as vaccine approach by its ability to inhibit HIV-1 and co-infecting pathogens: The role of its lipid fraction carrier

Donatien Mavoungou, M Owononze, J Ndong, B. M Taung Mve, G Maka, B Ongali and Elie Mavoungou
Université des Sciences de la Santé, Cambodia

Immunorex TM as an antagonist of HIV-1 Tat, removes the overproduction of IL-10, contributing to the restoration of TH1 and TH2 balance and prevents cooperation between HIV-1 and co-infecting pathogens. Mass spectroscopy of Immunorex TM revealed presence of DHEA, salicin, threonine, fatty acids among others molecules, having antiviral, antibacterial, anti pyretic, anti inflammatory and anti cancer activities.

Objective: Analyse ImmunorexTM lipids fraction (LCF) as a putative source of antibiotics.

LCF microbicidal activity was assessed by the sensitivity using the methods of Chapman and Sabourreau. Escherichia coli (E.coli), Staphylococcus aureus, Pseudomonas and Klebsiella were isolated from the urine of HIV-1-infected patients diagnosed by western Blot technique. Various antibiotic disc (ABD) have been impregnated at 25°C with the LCF (Group 1), then dried and incubated with various germs isolated in parallel with native counter parts in Group 2. The diameters were measured (cm) to compare sensitivity between groups. LCF showed significant increase of respective antibiotics via diameter (cm): 16→28; 10→18 + Ac Clavulamique for Staphylococcus aureus, LCF increased sensitivities of Amoxicilline, Cefotaxime (0→32), Netelmicine ( 20→34); Rifampicine (13→22).Cefotaxime (21→24); Aztreonam (41→48) and Amoxicilline Ac clavulamique ( 0→18) for E. coli while for Klebsiella, sensitivities to ABD was: Amoxicilline + Ac. clavulamique (20→24;28→30); Netelmicine (20→24; 20→28); LCF showed while for Pseudomonas, negligible sensitivities to ABD. ImmunorexTM revealed potential microbicide activity that may contribute to block HIV-1 infection and the cooperation with co-infecting pathogens, protecting the unavoidable TH1 and TH2 balance in a drug and vaccine approach against HIV-1, including Tat Oyi vaccine as suggested by Biosantech, France.

Biography
Donatien Mavoungou is the Director of the Research Center on Hormonal Pathologies (CRPH) Gabon. He is the Invited Member at McGill University Aids Center (Montreal) and at Genomic Chair of Canada. He authored more than 150 publications. He discovered IMMUNOREX TM DM28 inhibiting HIV-1 replication. He is Professor of Biochemistry and Endocrinology at the University of Health Science Libreville, Gabon. Field: HIV, Metabolic disorders, HAART, Hormonal Therapy. He received the Prize of the National Center for Scientific Research in 2009 and 2012. (Gabon). He is the Blue Ribbon Presenter, recipient of the Glaxo Smith Klein Award at ISHIB, Orlando (USA, 2007). He is the Member of WABT Academy.

crph2000@yahoo.fr